Ad is loading...
NTLA
Price
$13.65
Change
-$0.84 (-5.80%)
Updated
Dec 5, 04:59 PM (EDT)
76 days until earnings call
PGEN
Price
$0.77
Change
-$0.03 (-3.75%)
Updated
Dec 5, 04:59 PM (EDT)
82 days until earnings call
Ad is loading...

NTLA vs PGEN

Header iconNTLA vs PGEN Comparison
Open Charts NTLA vs PGENBanner chart's image
Intellia Therapeutics
Price$13.65
Change-$0.84 (-5.80%)
Volume$50.09K
CapitalizationN/A
Precigen
Price$0.77
Change-$0.03 (-3.75%)
Volume$13K
CapitalizationN/A
NTLA vs PGEN Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NTLA vs. PGEN commentary
Dec 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and PGEN is a StrongBuy.

COMPARISON
Comparison
Dec 06, 2024
Stock price -- (NTLA: $14.49 vs. PGEN: $0.80)
Brand notoriety: NTLA and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 59% vs. PGEN: 167%
Market capitalization -- NTLA: $1.49B vs. PGEN: $235.73M
NTLA [@Biotechnology] is valued at $1.49B. PGEN’s [@Biotechnology] market capitalization is $235.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 3 bearish.
  • PGEN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PGEN.

Price Growth

NTLA (@Biotechnology) experienced а -4.73% price change this week, while PGEN (@Biotechnology) price change was -11.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.80%. For the same industry, the average monthly price growth was -1.99%, and the average quarterly price growth was +8.82%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-1.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.49B) has a higher market cap than PGEN($236M). PGEN YTD gains are higher at: -39.933 vs. NTLA (-52.476). PGEN has higher annual earnings (EBITDA): -136.11M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. PGEN (28.6M). PGEN has less debt than NTLA: PGEN (5.75M) vs NTLA (102M). NTLA has higher revenues than PGEN: NTLA (43.1M) vs PGEN (3.96M).
NTLAPGENNTLA / PGEN
Capitalization1.49B236M632%
EBITDA-527.52M-136.11M388%
Gain YTD-52.476-39.933131%
P/E RatioN/AN/A-
Revenue43.1M3.96M1,088%
Total Cash658M28.6M2,301%
Total Debt102M5.75M1,774%
FUNDAMENTALS RATINGS
NTLA vs PGEN: Fundamental Ratings
NTLA
PGEN
OUTLOOK RATING
1..100
1213
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (32) in the Biotechnology industry is in the same range as PGEN (54) in the null industry. This means that NTLA’s stock grew similarly to PGEN’s over the last 12 months.

NTLA's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that NTLA’s stock grew similarly to PGEN’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as PGEN (98) in the null industry. This means that NTLA’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (64) in the null industry is in the same range as NTLA (85) in the Biotechnology industry. This means that PGEN’s stock grew similarly to NTLA’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPGEN
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVBAX29.940.24
+0.81%
JHancock Balanced A
LVOPX19.620.07
+0.36%
Lord Abbett Value Opportunities P
CPCRX4.30N/A
N/A
Comstock Capital Value I
IWTTX12.16-0.03
-0.25%
Voya Global High Dividend Low Vol PortS2
CMALX27.24-0.09
-0.33%
Crawford Multi-Asset Income

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.09%
VCYT - NTLA
69%
Closely correlated
+0.98%
EDIT - NTLA
68%
Closely correlated
+0.51%
BEAM - NTLA
66%
Closely correlated
+0.15%
CRSP - NTLA
61%
Loosely correlated
-0.20%
PRME - NTLA
58%
Loosely correlated
+1.92%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-6.82%
CRSP - PGEN
54%
Loosely correlated
-0.20%
NTLA - PGEN
53%
Loosely correlated
-1.09%
BEAM - PGEN
52%
Loosely correlated
+0.15%
ARWR - PGEN
52%
Loosely correlated
-11.35%
RCKT - PGEN
50%
Loosely correlated
+0.59%
More